Processing

Please wait...

Settings

Settings

Goto Application

1. WO2013001542 - AN OPTIMIZED BILAYERED TABLET WITH TWO ACTIVE ANTIBIOTICS: CEFADROXIL AND CLAVULANIC ACID

Publication Number WO/2013/001542
Publication Date 03.01.2013
International Application No. PCT/IN2011/000686
International Filing Date 03.10.2011
IPC
A61K 9/20 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
A61K 9/28 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, lozenges or tablets
28Dragees; Coated pills or tablets
A61K 31/43 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
429condensed with heterocyclic ring systems
43Compounds containing 4-thia-1-azabicyclo heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
A61K 31/545 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
54having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
542ortho- or peri-condensed with heterocyclic ring systems
545Compounds containing 5-thia-1-azabicyclo octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine
CPC
A61K 31/43
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
425Thiazoles
429condensed with heterocyclic ring systems
43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
A61K 31/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
54having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
542ortho- or peri-condensed with heterocyclic ring systems
545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins, ; cefaclor, or cephalexine
A61K 9/209
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
2072characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
209containing drug in at least two layers or in the core and in at least one outer layer
A61K 9/2866
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
28Dragees; Coated pills or tablets ; , e.g. with film or compression coating
2806Coating materials
2833Organic macromolecular compounds
286Polysaccharides, e.g. gums; Cyclodextrin
2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Applicants
  • AGGARWAL, Kumar, Vijay [IN]/[IN]
  • GOEL, Sanjeev [IN]/[IN]
  • MISHRA, Umakant [IN]/[IN]
Inventors
  • AGGARWAL, Kumar, Vijay
  • GOEL, Sanjeev
  • MISHRA, Umakant
Common Representative
  • AGGARWAL, Kumar, Vijay [IN]/[IN]
Priority Data
1853/DEL/201130.06.2011IN
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) AN OPTIMIZED BILAYERED TABLET WITH TWO ACTIVE ANTIBIOTICS: CEFADROXIL AND CLAVULANIC ACID
(FR) COMPRIMÉ BICOUCHES OPTIMISÉ COMPRENANT DEUX ANTIBIOTIQUES ACTIFS : LE CÉFADROXIL ET L'ACIDE CLAVULANIQUE
Abstract
(EN)
This invention discloses optimized pharmaceutical formulation for bilayer tablet form comprising at least one antibiotic or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said one aqueous diluent, binder, disintigrants, Film forming agents, moisture barrier agents. Both ingredient in a single dosages form at same time with high solubility and stability by over coming cross interaction or chemical incompatibilities between two different physical, chemical and physicochemical drug molecules by physical separation, and to enable the development of different drug release profile both in immediate release and immediate release with extended release and promoting patient convenience and compliance.
(FR)
La présente invention concerne une formulation pharmaceutique optimisée pour une forme galénique de type comprimé bicouches comprenant au moins un antibiotique ou un sel pharmaceutiquement acceptable de celui-ci, et au moins un agent améliorant la dissolution en quantité suffisante pour sensiblement dissoudre ledit agent diluant aqueux, un liant, des agents délitants, des agents formant un film, des agents barrières contre l'humidité. L'invention concerne ainsi les deux principes actifs dans des formes galéniques unitaires présentant, en même temps, une solubilité et une stabilité élevées en éliminant les interactions croisées ou les incompatibilités chimiques entre deux molécules médicamenteuses physiques, chimiques et physicochimiques différentes grâce à une séparation physique, et en permettant le développement de profils de libération différents pour les médicaments à la fois pour une libération immédiate et pour une libération immédiate ajoutée à une libération prolongée et en favorisant le confort et l'observance du patient.
Also published as
Latest bibliographic data on file with the International Bureau